Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434180 | 0.85 | ALPL (0.59) | CA12CA1CA2CA9ALPL | |
| SCHEMBL10049127 | 0.85 | KMT2A (0.45) | CA12CA1CA2CA9ALPL | |
| SCHEMBL10049128 | 0.84 | CCNT1 (0.47) | CYP1A2CYP3A4CYP2D6CYP2C9TACR2 | |
| SCHEMBL3435955 | 0.84 | CNR1 (0.43) | HSP90AA1HSP90AB1ALPLUSP2HTT | |
| SCHEMBL3435989 | 0.84 | MARS1 (0.46) | HSP90AA1HSP90AB1USP2HTTKMT2A | |
| SCHEMBL10049411 | 0.83 | ALPL (0.54) | CYP2C9CA12CA1CA2CA9 | |
| SCHEMBL3436590 | 0.82 | CA12 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C9TACR2 | |
| SCHEMBL3436656 | 0.78 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1ALDH1A1CRHR1TP53 | |
| SCHEMBL3435623 | 0.76 | MARS1 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C9TACR2 | |
| SCHEMBL2565586 | 0.76 | MAPT (0.56) | CYP1A2CYP3A4CYP2D6CYP2C9TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| WO-2012002527-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | あすか製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | CYP1A2 4179/4885CYP3A4 4009/4885CYP2D6 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.